CO [China Cord Blood] 20-F: FORM 20-F o OR x OR o For

[FORM 20-F o OR x OR o For the transition period from to OR o Date of event requiring this shell company report: China Cord Blood Corporation Cayman Islands (Jurisdiction of incorporation or organization) 48 th Floor, Bank of China Tower 1 Garden Road Central, Hong Kong S.A.R. Albert Chen +852 3605 8180 albert.chen@chinacordbloodcorp.com 48 th Floor, Bank of China] [List of Subsidiaries Name Jurisdiction China Cord Blood Services Corporation Cayman Islands China Stem Cells Holdings Limited Cayman Islands Beijing Jiachenhong Biological Technologies Co., Ltd. People’s Republic of China Guangzhou Municipality Tianhe Nuoya Bio-engineering Co., Ltd. People’s Republic of China Zhejiang Lukou Biotechnology Co., Ltd. People’s Republic of China China Stem Cells (East) Company Limited British Virgin Islands China Stem] [Certification I, Ting Zheng, certify that: 1. I have reviewed this annual report on Form 20-F of China Cord Blood Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [Certification I, Albert Chen, certify that: 1. I have reviewed this annual report on Form 20-F of China Cord Blood Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [Certification CHINA CORD BLOOD CORPORATION July 28, 2016 Ting Zheng Chief Executive Officer July 28, 2016 Albert Chen Chief Financial Officer (Principal Financial Officer) EX-13.1 5 a16-7975_1ex13d1.htm EX-13.1] [Consent of Independent Registered Public Accounting Firm The Board of Directors We consent to the incorporation by reference in the registration statements No. 333-183143 and No. 333-191121 on Form F-3 of China Cord Blood Corporation of our report dated July 31, 2015, with respect to the consolidated balance sheet of China Cord Blood Corporation and subsidiaries as of March 31,] [Consent of Independent Registered Public Accounting Firm The Board of Directors We consent to the incorporation by reference in the registration statements No. 333-183143 and No. 333-191121 on Form F-3 of China Cord Blood Corporation of our reports dated July 28, 2016, with respect to the consolidated balance sheet of China Cord Blood Corporation and subsidiaries as of March 31,] [Letter from Independent Registered Public Accounting Firm Ladies and Gentlemen: We were previously principal accountants for China Cord Blood Corporation and, under the date of July 31, 2015, we reported on the consolidated financial statements of China Cord Blood Corporation as of March 31, 2014 and 2015 and for each of the years in the three-year period ended March 31,]

By | 2016-08-02T11:40:56+00:00 July 28th, 2016|Categories: Chinese Stocks, CO, Webplus ver|Tags: , , , , , |0 Comments

CO [China Cord Blood] 20-F: (Original Filing)

[FORM 20-F o OR x OR o For the transition period from to OR o Date of event requiring this shell company report: China Cord Blood Corporation Cayman Islands (Jurisdiction of incorporation or organization) 48 th Floor, Bank of China Tower 1 Garden Road Central, Hong Kong S.A.R. Albert Chen +852 3605 8180 albert.chen@chinacordbloodcorp.com 48 th Floor, Bank of China] [List of Subsidiaries Name Jurisdiction China Cord Blood Services Corporation Cayman Islands China Stem Cells Holdings Limited Cayman Islands Beijing Jiachenhong Biological Technologies Co., Ltd. People’s Republic of China Guangzhou Municipality Tianhe Nuoya Bio-engineering Co., Ltd. People’s Republic of China Zhejiang Lukou Biotechnology Co., Ltd. People’s Republic of China China Stem Cells (East) Company Limited British Virgin Islands China Stem] [Certification I, Ting Zheng, certify that: 1. I have reviewed this annual report on Form 20-F of China Cord Blood Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [Certification I, Albert Chen, certify that: 1. I have reviewed this annual report on Form 20-F of China Cord Blood Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [Certification CHINA CORD BLOOD CORPORATION July 28, 2016 Ting Zheng Chief Executive Officer July 28, 2016 Albert Chen Chief Financial Officer (Principal Financial Officer) EX-13.1 5 a16-7975_1ex13d1.htm EX-13.1] [Consent of Independent Registered Public Accounting Firm The Board of Directors We consent to the incorporation by reference in the registration statements No. 333-183143 and No. 333-191121 on Form F-3 of China Cord Blood Corporation of our report dated July 31, 2015, with respect to the consolidated balance sheet of China Cord Blood Corporation and subsidiaries as of March 31,] [Consent of Independent Registered Public Accounting Firm The Board of Directors We consent to the incorporation by reference in the registration statements No. 333-183143 and No. 333-191121 on Form F-3 of China Cord Blood Corporation of our reports dated July 28, 2016, with respect to the consolidated balance sheet of China Cord Blood Corporation and subsidiaries as of March 31,] [Letter from Independent Registered Public Accounting Firm Ladies and Gentlemen: We were previously principal accountants for China Cord Blood Corporation and, under the date of July 31, 2015, we reported on the consolidated financial statements of China Cord Blood Corporation as of March 31, 2014 and 2015 and for each of the years in the three-year period ended March 31,]

By | 2016-08-02T11:38:49+00:00 July 28th, 2016|Categories: Chinese Stocks, CO, SEC Original|Tags: , , , , , |0 Comments

CO [China Cord Blood] 20-F: FORM 20-F o OR x OR o For

[FORM 20-F o OR x OR o For the transition period from to OR o Date of event requiring this shell company report: China Cord Blood Corporation Cayman Islands (Jurisdiction of incorporation or organization) 48 th Floor, Bank of China Tower 1 Garden Road Central, Hong Kong S.A.R. Albert Chen +852 3605 8180 albert.chen@chinacordbloodcorp.com 48 th Floor, Bank of China] [List of Subsidiaries Name Jurisdiction China Cord Blood Services Corporation Cayman Islands China Stem Cells Holdings Limited Cayman Islands Beijing Jiachenhong Biological Technologies Co., Ltd. People’s Republic of China Guangzhou Municipality Tianhe Nuoya Bio-engineering Co., Ltd. People’s Republic of China Zhejiang Lukou Biotechnology Co., Ltd. People’s Republic of China China Stem Cells (East) Company Limited British Virgin Islands China Stem] [Certification I, Ting Zheng, certify that: 1. I have reviewed this annual report on Form 20-F of China Cord Blood Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [Certification I, Albert Chen, certify that: 1. I have reviewed this annual report on Form 20-F of China Cord Blood Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [Certification CHINA CORD BLOOD CORPORATION July 28, 2016 Ting Zheng Chief Executive Officer July 28, 2016 Albert Chen Chief Financial Officer (Principal Financial Officer) EX-13.1 5 a16-7975_1ex13d1.htm EX-13.1] [Consent of Independent Registered Public Accounting Firm The Board of Directors We consent to the incorporation by reference in the registration statements No. 333-183143 and No. 333-191121 on Form F-3 of China Cord Blood Corporation of our report dated July 31, 2015, with respect to the consolidated balance sheet of China Cord Blood Corporation and subsidiaries as of March 31,] [Consent of Independent Registered Public Accounting Firm The Board of Directors We consent to the incorporation by reference in the registration statements No. 333-183143 and No. 333-191121 on Form F-3 of China Cord Blood Corporation of our reports dated July 28, 2016, with respect to the consolidated balance sheet of China Cord Blood Corporation and subsidiaries as of March 31,] [Letter from Independent Registered Public Accounting Firm Ladies and Gentlemen: We were previously principal accountants for China Cord Blood Corporation and, under the date of July 31, 2015, we reported on the consolidated financial statements of China Cord Blood Corporation as of March 31, 2014 and 2015 and for each of the years in the three-year period ended March 31,]

By | 2016-08-02T11:40:07+00:00 July 28th, 2016|Categories: Chinese Stocks, CO, Webplus ver|Tags: , , , , , |0 Comments

CO [China Cord Blood] 6-K: (Original Filing)

[China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2016 Added 14,472 New Subscribers in 4Q16 4Q16 Revenue Amounted to RMB156.8 Million ($24.3 Million) 4Q16 Operating Income Amounted to RMB39.7 Million ($6.2 Million) Conference Call to be Held on June 15, 2016 at 8:00 a.m. ET HONG KONG, China, June 14, 2016 —] [FORM 6-K For the month of June 2016 CHINA CORD BLOOD CORPORATION 48 th Floor, Bank of China Tower Form 20-F x o o o Yes o x EXPLANATORY NOTE 2 Results of Operations and Financial Condition Following this cover page are the preliminary unaudited condensed consolidated financial results for the three months and year ended March 31, 2016 of]

By | 2016-06-21T12:20:28+00:00 June 14th, 2016|Categories: Chinese Stocks, CO, SEC Original|Tags: , , , , , |0 Comments

CO [China Cord Blood] 6-K: China Cord Blood Corporation Reports Financial Results for

[China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2016 Added 14,472 New Subscribers in 4Q16 4Q16 Revenue Amounted to RMB156.8 Million ($24.3 Million) 4Q16 Operating Income Amounted to RMB39.7 Million ($6.2 Million) Conference Call to be Held on June 15, 2016 at 8:00 a.m. ET HONG KONG, China, June 14, 2016 —] [FORM 6-K For the month of June 2016 CHINA CORD BLOOD CORPORATION 48 th Floor, Bank of China Tower Form 20-F x o o o Yes o x EXPLANATORY NOTE 2 Results of Operations and Financial Condition Following this cover page are the preliminary unaudited condensed consolidated financial results for the three months and year ended March 31, 2016 of]

By | 2016-06-21T12:21:15+00:00 June 14th, 2016|Categories: Chinese Stocks, CO, Webplus ver|Tags: , , , , , |0 Comments

CO [China Cord Blood] 6-K: (Original Filing)

[China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2016 3Q16 Added 15,603 New Subscribers 3Q16 Revenue Up 1.6% YOY to RMB169.4 Million ($26.1 Million) 3Q16 Operating Income Amounted to RMB50.8 Million ($7.8 Million) Conference Call to be Held on March 1, 2016 at 8:00 a.m. ET HONG KONG, China, February 29,] [FORM 6-K For the month of February 2016 CHINA CORD BLOOD CORPORATION 48 th Floor, Bank of China Tower Form 20-F x Form 40-F o o o Yes o No x EXPLANATORY NOTE 2 Results of Operations and Financial Condition]

By | 2016-03-27T07:46:44+00:00 February 29th, 2016|Categories: Chinese Stocks, CO, SEC Original|Tags: , , , , , |0 Comments

CO [China Cord Blood] 6-K: China Cord Blood Corporation Reports Financial Results for

[China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2016 3Q16 Added 15,603 New Subscribers 3Q16 Revenue Up 1.6% YOY to RMB169.4 Million ($26.1 Million) 3Q16 Operating Income Amounted to RMB50.8 Million ($7.8 Million) Conference Call to be Held on March 1, 2016 at 8:00 a.m. ET HONG KONG, China, February 29,] [FORM 6-K For the month of February 2016 CHINA CORD BLOOD CORPORATION 48 th Floor, Bank of China Tower Form 20-F x Form 40-F o o o Yes o No x EXPLANATORY NOTE 2 Results of Operations and Financial Condition]

By | 2016-03-27T07:48:16+00:00 February 29th, 2016|Categories: Chinese Stocks, CO, Webplus ver|Tags: , , , , , |0 Comments

CO [China Cord Blood] SC 13G/A: (Original Filing)

[SCHEDULE 13G/A Amendment No. 10 China Cord Blood Corporation (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 698659109 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) ☐ Rule 13d-1(b) ☒ Rule 13d-1(c) ☐ Rule 13d-1(d) *The remainder of this cover page shall be filled out for a]

By | 2016-03-27T07:50:06+00:00 February 12th, 2016|Categories: Chinese Stocks, CO, SEC Original|Tags: , , , , , |0 Comments

CO [China Cord Blood] SC 13G/A: SCHEDULE 13G/A Amendment No. 10 China Cord Blood

[SCHEDULE 13G/A Amendment No. 10 China Cord Blood Corporation (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 698659109 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) ☐ Rule 13d-1(b) ☒ Rule 13d-1(c) ☐ Rule 13d-1(d) *The remainder of this cover page shall be filled out for a]

By | 2016-03-27T07:51:24+00:00 February 12th, 2016|Categories: Chinese Stocks, CO, Webplus ver|Tags: , , , , , |0 Comments

CO [China Cord Blood] SC 13D/A: (Original Filing)

[Confidential Agreement to Purchase Assets by Share Issuance and Cash Payment In relation to Nanjing Xinjiekou Department Store Co., Ltd. By and among Nanjing Xinjiekou Department Store Co., Ltd. Golden Meditech Stem Cells (BVI) Company Limited and Golden Meditech Holdings Limited January 2016 Confidential Table of Contents ARTICLE 1 DEFINITIONS 2 ARTICLE 2 TRANSACTION ARRANGEMENTS 7 ARTICLE 3 CLOSING CONDITIONS] [Confidential Share Sale and Purchase Agreement In relation to China Cord Blood Corporation By and among Nanjing Xinjiekou Department Store Co., Ltd. and Golden Meditech Stem Cells (BVI) Company Limited Golden Meditech Holdings Limited January 2016 Confidential Table of Contents ARTICLE 1 DEFINITIONS 2 ARTICLE 2 TRANSACTION ARRANGEMENTS 6 ARTICLE 3 CLOSING CONDITIONS 9] [Profit Compensation Agreement By and between Nanjing Xinjiekou Department Store Co., Ltd. and Golden Meditech Stem Cells (BVI) Company Limited January 2016 Profit Compensation Agreement Profit Compensation Agreement Agreement This Party A: Nanjing Xinjiekou Department Store Co., Ltd. Address: 1 South Zhongshan Road, Qinhuai District, Nanjing, Jiangsu Province Legal Representative: Huaizhen Yang Party B: Golden Meditech Stem Cells (BVI) Company] [Dated this [ ] B E T W E E N : [ ] (as Chargor) AND GOLDEN MEDITECH STEM CELLS (BVI) LIMITED (as Chargee) AND CHINA CORD BLOOD CORPORATION SHARE CHARGE over TABLE OF CONTENTS 1. INTERPRETATION 1 2. 4 3. CHARGOR’S COVENANTS 5 4. COMPANY’S COVENANTS 6] [Dated this [ ] B E T W E E N : [ ] (as Chargor) AND GOLDEN MEDITECH STEM CELLS (BVI) LIMITED (as Chargee) AND CHINA CORD BLOOD CORPORATION SHARE CHARGE over shares representing [34.6%] of the issued share capital of China Cord Blood Corporation TABLE OF CONTENTS 1. INTERPRETATION 1 2. 4 3. CHARGOR’S COVENANTS 5 4. COMPANY’S] []

By | 2016-03-27T07:52:44+00:00 January 7th, 2016|Categories: Chinese Stocks, CO, SEC Original|Tags: , , , , , |0 Comments
Skip to toolbar